کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3286003 | 1209278 | 2016 | 6 صفحه PDF | دانلود رایگان |
SummaryBackgroundTo determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC).MethodsA computer-based search was performed. Randomised trials comparing RFA plus TACE and RFA alone for treatment of HCC were included in this meta-analysis. The outcome of interest for our analysis was survival (recurrence-free survival and overall survival).ResultsEight trials with 648 patients were eligible for this meta-analysis. Our pooled results suggest that RFA plus TACE is associated with a significant advantage in recurrence-free survival (RFS) (HR = 0.58; 95% CI = 0.42–0.80, P = 0.001), and overall survival (OS) (HR = 0.60; 95% CI = 0.47–0.76, P < 0.001).ConclusionTACE combined with RFA was more effective than RFA alone, especially for treatment for intermediate and large-size hepatic tumours or younger patients with HCC.
Journal: Clinics and Research in Hepatology and Gastroenterology - Volume 40, Issue 3, June 2016, Pages 309–314